Coherus Oncology (CHRS) Earnings Date & Reports

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers... Show more

Industry: #Biotechnology

Get AI intraday signals

A.I. Advisor

published Earnings

CHRS is expected to report earnings to fall 33.11% to -23 cents per share on July 31

Coherus Oncology CHRS Stock Earnings Reports

Q2'25

Est.

$-0.23

Q1'25

Missed

by $2.05

Q4'24

Beat

by $0.02

Q3'24

Beat

by $0.15

Q2'24

Beat

by $0.11

The last earnings report on May 13 showed earnings per share of -34 cents, missing the estimate of $1.70. With 1.23M shares outstanding, the current market capitalization sits at 83.59M.

View a ticker or compare two or three

Compare

CHRS